Chemotherapy combined with Endostar as salvage treatment for EGFR‐tyrosine kinase inhibitor primary resistance in an advanced non‐small cell lung cancer patient with EGFR L858R mutation and ROS1 fusion: A case report

EGFR‐activating mutations have been recognized as the most important predictor of response to EGFR‐tyrosine kinase inhibitors (TKIs); however, 20–30% of patients harboring EGFR‐activating mutations show poor responses. The mechanisms of such EGFR‐TKI primary resistance are still poorly understood. I...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiu, Dong, Zhang, Yu, Xue, Ying‐bo, Shen, Qi, Li, Hang, Huang, Ping, Hu, Jian‐jun, Wang, Yong‐sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2019
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449238/
https://www.ncbi.nlm.nih.gov/pubmed/30775851
http://dx.doi.org/10.1111/1759-7714.13003

Ejemplares similares

Ejemplares similares